相关实验视频
Updated: May 29, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.4K
一种对ROS有反应的TPP修饰的tanshinone IIA微粒改善了DOX诱导的心力衰竭
Yan Zhao1, Jiahua Wang2, Zixu Zhang2
1Dalian Medical University, Dalian, Liaoning, China 116044; Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital), Dalian, Liaoning, China 116024.
International journal of pharmaceutics
|February 8, 2025
概括
这项研究开发了新型反应性氧物种 (ROS) 响应性细胞以准心脏线粒体,通过减少氧化应激和炎症来有效治疗心力衰竭 (HF).
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 心血管研究研究心血管研究
背景情况:
- 心力衰竭 (HF) 由于其患病率和对当前治疗方法的耐药性而构成重大临床挑战.
- 现有的策略往往无法改善临床结果,需要新的治疗方法.
- 准心肌细胞线粒体提供了一种有前途的策略来对抗HF.
研究的目的:
- 开发和评估微环境响应的细胞,以向向心肌细胞线粒体提供高频率的细胞.
- 为了研究这些小粒在改善多克索鲁比 (DOX) 诱导的心力衰竭方面的疗效.
主要方法:
- 构建反应性氧物种 (ROS) 响应的三酸 (TPP) 修饰的坦辛IIA (TIIA) 微粒 (TK-TPP-TIIA@Ms).
- 在小粒体内封装TIIA,使用TPP结合的DSPE-PEG2000进行向和ROS可切割链接器 (TK).
- 在HF模型中的氧化应激,亡和炎症的治疗中,微细胞表现的体外和体内评估.
主要成果:
- 成功制备TK-TPP-TIIA@Ms,具有有利的物理化学特性和安全性.
- 在体外:增强了细胞吸收,减少了ROS,抑制了炎症和亡,并在H9c2细胞中恢复了线粒体膜潜力.
- 在体内:改善心肌损伤,减少亡和炎症,改善氧化应激在DOX诱导的HF的小鼠模型.
结论:
- TK-TPP-TIIA@Ms显示出作为治疗心脏病的有效和安全的向治疗的巨大潜力.
- 这种小胞系统是未来心力衰竭治疗策略的有希望的候选者.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
504
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
504
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
374
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374